TrialNature communications2025

Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 study.

François Rannou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.